Monograph Details
|
|
Urogenital System
> Miscellaneous urogenital disorders
|
|
FOSRENOL |
| Manufacturer |
|
Shire US, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Phosphate binder. |
| Generic Name |
|
Lanthanum carbonate 250mg, 500mg, 750mg, 1000mg; chew tabs. |
| Indications |
|
To reduce serum phosphate in end-stage renal disease. |
| Children |
|
Not recommended. |
| Adults |
|
Take with meals; chew tabs completely. Initially 750mg–1.5g/day in divided doses. Titrate at 2–3 wk intervals in increments of 750mg/day based on serum phosphate. Usual range: 1.5g–3g; usual max 3.75g/day. |
| Precautions |
|
Acute peptic ulcer. Ulcerative colitis. Crohn's disease. Bowel obstruction. Monitor phosphate, calcium. Labor & delivery. Pregnancy (Cat.C); not recommended. Nursing mothers. |
| Interactions |
|
Separate dosing of drugs that interact with antacids by 2 hrs. May interfere with abdominal x-ray. |
| Adverse Reactions |
|
GI upset (usually transient), dialysis graft occlusion, abdominal pain, constipation. |
| How Supplied |
Tabs 250mg—90
500mg patient pack (2 x 45 tabs)—1
750mg patient pack (6 x 15 tabs)—1
1000mg patient pack (9 x 10 tabs)—1 |
|
|
|
|
